Andrew Aromando
Directeur des opérations chez AMBRX INC
Profil
Andrew P.
Aromando is currently the Chief Operating Officer at Ambrx, Inc. and Ambrx Biopharma Cayman, Inc. He previously worked as the SVP-Commercial Development & Operations at Tamir Biotechnology, Inc. and as the Vice President-North American Business Development at Innovex LP from 2000 to 2004.
He also served as the Chief Operating Officer at Ambrx Biopharma, Inc. Mr. Aromando completed his undergraduate degree at The College of New Jersey and his graduate degree at Rutgers State University of New Jersey.
Postes actifs de Andrew Aromando
| Sociétés | Poste | Début |
|---|---|---|
| AMBRX INC | Directeur des opérations | 01/04/2023 |
Ambrx Biopharma, Inc.
 Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | Directeur des opérations | 28/04/2023 |
Anciens postes connus de Andrew Aromando
| Sociétés | Poste | Fin |
|---|---|---|
Innovex LP
 Innovex LP Miscellaneous Commercial ServicesCommercial Services Part of Quintiles Transnational Corp., Innovex LP is a company that provides contract product development services. The company is based in Durham, NC. | Corporate Officer/Principal | 01/01/2004 |
Tamir Biotechnology, Inc.
 Tamir Biotechnology, Inc. Medical SpecialtiesHealth Technology Tamir Biotechnology, Inc. engages in the discovering and developing of new class therapeutic drugs for the treatment of cancer and other pathological conditions. The firm's proprietary drug discovery program is also the basis for the development of recombinant designed RNases for chemical conjugation and fusion products with various targeting moieties, such as monoclonal antibodies, growth factors, and cytokines. The company was founded on August 24, 1981 and is headquartered in Short Hills, NJ. | Directeur des opérations | - |
Formation de Andrew Aromando
| The College of New Jersey | Undergraduate Degree |
| Rutgers State University of New Jersey | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Tamir Biotechnology, Inc.
Tamir Biotechnology, Inc. Medical SpecialtiesHealth Technology Tamir Biotechnology, Inc. engages in the discovering and developing of new class therapeutic drugs for the treatment of cancer and other pathological conditions. The firm's proprietary drug discovery program is also the basis for the development of recombinant designed RNases for chemical conjugation and fusion products with various targeting moieties, such as monoclonal antibodies, growth factors, and cytokines. The company was founded on August 24, 1981 and is headquartered in Short Hills, NJ. | Health Technology |
Innovex LP
Innovex LP Miscellaneous Commercial ServicesCommercial Services Part of Quintiles Transnational Corp., Innovex LP is a company that provides contract product development services. The company is based in Durham, NC. | Commercial Services |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | Health Technology |
Ambrx, Inc.
 Ambrx, Inc. Pharmaceuticals: MajorHealth Technology Ambrx, Inc. engages in discovering and developing of protein therapeutics. It offers non-native amino acids through expanded genetic code to both generate novel bio-therapeutics. The company was founded by Richard DiMarchi, Peter G. Schultz, and Troy E. Wilson on April 15, 2003 and is headquartered in La Jolla, CA. | Health Technology |